Wet Age-related Macular Degeneration Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Positive-controlled, Seamless Design Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (Code MW02) in the Treatment of Neovascular (Wet) Age-related Macular Degeneration (nAMD)
The purpose of this study is to compare the efficacy and safety of MW02 versus Lucentis in the treatment of neovascular age-related macular degeneration.The study was divided into two stages. The first stage was to explore the dose and the second stage was to explore the frequency of administration.
Status | Recruiting |
Enrollment | 433 |
Est. completion date | June 30, 2024 |
Est. primary completion date | May 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Main Inclusion Criteria: 1. fully understand this research and sign ICF; Willing to follow and be able to complete all study procedures; 2. Age = 50 years old, < 80 years old, male or female; 3. Active CNV lesions in fovea and/or parafovea secondary to nAMD , which have not been treated in the study eye 3 months before screening; 4. The BCVA of the study eye is 73~24 letters (including boundary value), which is equivalent to 20/40 to 20/320 of Snellen's visual acuity chart. 5. CNV area of the study eye=50% of the total lesion area. Main Exclusion Criteria: 1. There is subretinal or intraretinal hemorrhage in the study eye, and the bleeding area is = 50% of the total lesion area, or it is located in the fovea and the area is = 1 optic disc area; 2. The study eye has scar, fibrosis, geographic atrophy and dense hard exudation under the fovea. 3. CNV caused by non-nAMD exists in the study eye (such as trauma, pathological myopia, multifocal choroiditis, ocular histoplasmosis, vascular stripes, etc.); 4. The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine (diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, macular epiretinal membrane, retinal pigment epithelium tear involving macular, vitreous macular traction syndrome, optic nerve disease, etc.); 5. Intravitreous hemorrhage occurred in the study eye within 30 days before the first administration. 6. The study eye has received the following intraocular surgery within 90 days, or has previously received various macular laser treatments (such as macular transposition, transpupillary thermotherapy, macular photocoagulation, vitrectomy, optic nerve incision, optic nerve sheath incision, etc.) (except those who have received Vitepofin-photodynamic therapy, cataract surgery and YAG posterior capsulotomy more than 3 months before screening) or have performed external eye surgery within 30 days; 7. The study eye has used corticosteroids in the eye or in the whole body within 3 months or injected corticosteroids around the globe within 30 days before the first administration; 8. The study eye has poorly controlled glaucoma (defined as intraocular pressure=25 mmHg after anti-glaucoma treatment), and/or has received glaucoma filtering surgery (such as trabeculectomy, scleral bite, non-penetrating trabecular surgery, etc.); 9. The study eye has high myopia with diopter=8D 10. The study eye has refractive interstitial turbidity and/or myosis that affect fundus or OCT examination; 11. Aphakia (except intraocular lens) or rupture of posterior capsule of lens (except YAG laser posterior capsulotomy after intraocular lens implantation more than 30 days before the first administration); 12. Scleromalacia exists in the study eye. |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital of Sichuan University | Chengdu | Si Chuan |
Lead Sponsor | Collaborator |
---|---|
Mabwell (Shanghai) Bioscience Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in Best Corrected Visual Acuity (BCVA) | Change from Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study(ETDRS) letter score at week 52. | At week 52 | |
Secondary | Change from Baseline in BCVA | Change from Baseline in BCVA as measured by ETDRS letter score over the study duration. | baseline to week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00138632 -
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Terminated |
NCT04594681 -
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT03585556 -
AAVCAGsCD59 for the Treatment of Wet AMD
|
Phase 1 | |
Completed |
NCT03362190 -
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
|
Phase 2 | |
Not yet recruiting |
NCT04564937 -
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
Terminated |
NCT02005133 -
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
|
N/A | |
Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
Completed |
NCT03748784 -
ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
Phase 1 | |
Recruiting |
NCT04468997 -
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1 | |
Completed |
NCT04685369 -
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
|
||
Enrolling by invitation |
NCT04932980 -
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
|
N/A | |
Completed |
NCT03939767 -
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
|
||
Completed |
NCT03066258 -
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
|
Phase 1/Phase 2 | |
Terminated |
NCT01086761 -
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
|
Phase 1 | |
Recruiting |
NCT05727397 -
Efficacy and Safety of RC28-E Versus Aflibercept
|
Phase 3 | |
Completed |
NCT04884399 -
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
|
Phase 1 | |
Completed |
NCT04964089 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
|
Phase 3 | |
Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A | |
Terminated |
NCT00139282 -
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
|
Phase 3 |